Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Recent & Breaking News (TSXV:ARCH)

Grant of Options to Directors and Officers

GlobeNewswire December 18, 2023

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

GlobeNewswire December 13, 2023

Shares for Interest Debt Settlement

GlobeNewswire October 24, 2023

Arch Biopartners applies to test its kidney injury prevention drug

Jocelyn Aspa September 22, 2023

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

GlobeNewswire September 22, 2023

Arch Biopartners Engages Independent Trading Group as Market Maker

GlobeNewswire July 31, 2023

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

GlobeNewswire June 27, 2023

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

GlobeNewswire April 18, 2023

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

GlobeNewswire March 23, 2023

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

GlobeNewswire February 7, 2023

Shares for Interest Debt Settlement; Grants Options

GlobeNewswire December 15, 2022

Arch Biopartners (TSXV:ARCH) welcomes Farris Smith as a Strategic Advisor

Brieanna McCutcheon  October 5, 2022

Arch Biopartners Adds Farris Smith as a Strategic Advisor

GlobeNewswire October 5, 2022

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

GlobeNewswire August 5, 2022

Arch Biopartners' (TSXV:ARCH) trial receives approval to include LSALT Peptide

Caroline Egan  February 14, 2022

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

GlobeNewswire February 14, 2022

Shares for Interest Debt Settlement

GlobeNewswire February 8, 2022

Arch Biopartners (TSXV:ARCH) publishes data on lead drug candidate

Caroline Egan  February 3, 2022

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

GlobeNewswire February 3, 2022

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

GlobeNewswire January 4, 2022